Vetoquinol SA (EPA: VETO)

France flag France · Delayed Price · Currency is EUR
78.90
-1.60 (-1.99%)
Nov 20, 2024, 5:35 PM CET
-10.65%
Market Cap 933.59M
Revenue (ttm) 537.47M
Net Income (ttm) 47.14M
Shares Out 11.83M
EPS (ttm) 3.98
PE Ratio 19.81
Forward PE 16.24
Dividend 0.85 (1.06%)
Ex-Dividend Date Jun 4, 2024
Volume 466
Open 80.70
Previous Close 80.50
Day's Range 78.90 - 81.20
52-Week Range 77.90 - 110.00
Beta 0.94
Analysts n/a
Price Target n/a
Earnings Date Mar 21, 2025

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol... [Read more]

Sector Healthcare
Founded 1933
Employees 2,440
Stock Exchange Euronext Paris
Ticker Symbol VETO
Full Company Profile

Financial Performance

In 2023, Vetoquinol's revenue was 529.27 million, a decrease of -1.95% compared to the previous year's 539.78 million. Earnings were 55.56 million, an increase of 15.76%.

Financial Statements

News

There is no news available yet.